A novel GABAergic dysfunction in human Dravet syndrome

Abstract

Summary Objective Dravet syndrome is a rare neurodevelopmental disease, characterized by general cognitive impairment and severe refractory seizures. The majority of patients carry the gene mutation SCN1A, leading to a defective sodium channel that contributes to pathogenic brain excitability. A γ‐aminobutyric acid (GABAergic) impairment, as in other neurodevelopmental diseases, has been proposed as an additional mechanism, suggesting that seizures could be alleviated by GABAergic therapies. However, up to now the physiological mechanisms underlying the GABAergic dysfunction in Dravet syndrome are still unknown due to the scarce availability of this brain tissue. Here we studied, for the first time, human GABAA‐evoked currents using cortical brain tissue from Dravet syndrome patients. Methods We transplanted in Xenopus oocytes cell membranes obtained from brain tissues of autopsies of Dravet syndrome patients, tuberous sclerosis complex patients as a pathological comparison, and age‐matched controls. Additionally, experiments were performed on oocytes expressing human α1β2γ2 and α1β2 GABAA receptors. GABAA currents were recorded using the two‐microelectrodes voltage‐clamp technique. Quantitative real‐time polymerase chain reaction, immunohistochemistry, and double‐labeling techniques were carried out on the same tissue samples. Results We found (1) a decrease in GABA sensitivity in Dravet syndrome compared to controls, which was related to an increase in α4‐ relative to α1‐containing GABAA receptors; (2) a shift of the GABA reversal potential toward more depolarizing values in Dravet syndrome, and a parallel increase of the chloride transporters NKCC1/KCC2 expression ratio; (3) an increase of GABAA currents induced by low doses of cannabidiol both in Dravet syndrome and tuberous sclerosis complex comparable to that induced by a classical benzodiazepine, flunitrazepam, that still persists in γ‐less GABAA receptors. Significance Our study indicates that a dysfunction of the GABAergic system, considered as a feature of brain immaturity, together with defective sodium channels, can contribute to a general reduction of inhibitory efficacy in Dravet brain, suggesting that GABAA receptors could be a target for new therapies.

Erythropoietin Increases GABAA Currents in Human Cortex from TLE Patients

“…In agreement with our previous studies (Roseti et al, 2013;Ruffolo et al, 2018), this variability in I GABA amplitude was not dependent by which patient was used for membranes preparation, since each human sample was obtained from the same amount of tissue, but it was probably due to a different expression efficiency in the different oocytes.…”

Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?

“…Other studies also investigated the involvement of CBD on GABA A Rs mediated transmission: by using human tissues obtained from patients suffering of Dravet syndrome (DS) and tuberous sclerosis complex (TSC) it was demonstrated that CBD at 5 µM concentration is able to significantly increase GABA-evoked currents amplitude, acting as a positive allosteric modulator. This effect was totally reverted after a short wash-out [62] and was comparable to that of a typical benzodiazepine (BDZ), i.e., flunitrazepam. Indeed, CBD was able to significantly increase evoked GABA A Rs currents, both on α1and α2-containing receptors, with an efficacy that was very similar to the flunitrazepam.…”

Add‐on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy

“…In fact, the increase in TRPV1 might be one of the mechanisms promoting excitatory/inhibitory imbalance in epilepsy 17,18 and specifically in drug‐resistant epilepsy related to SYNGAP1 mutations. CBD is known to generate a rapid activation and desensitization of TRPV1 in a dose‐dependent manner 19–22 and might target in this way the TRPV1 increase induced by SYNGAP1 mutations resulting in seizures’ reduction.…”